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Abstract
Background: The objective of this research was to develop a disease-specific measure for fatigue in patients with
motor neurone disease (MND) by generating data that would fit the Rasch measurement model. Fatigue was
defined as reversible motor weakness and whole-body tiredness that was predominantly brought on by muscular
exertion and was partially relieved by rest.
Methods: Qualitative interviews were undertaken to confirm the suitability of a previously identified set of 52
neurological fatigue items as relevant to patients with MND. Patients were recruited from five U.K. MND clinics.
Questionnaires were administered during clinic or by post. A sub-sample of patients completed the questionnaire again
after 2-4 weeks to assess test-retest validity. Exploratory factor analyses and Rasch analysis were conducted on the item set.
Results: Qualitative interviews with ten MND patients confirmed the suitability of 52 previously identified
neurological fatigue items as relevant to patients with MND. 298 patients consented to completing the initial
questionnaire including this item set, with an additional 78 patients completing the questionnaire a second time
after 4-6 weeks. Exploratory Factor Analysis identified five potential subscales that could be conceptualised as
representing: ‘Energy’, ‘Reversible muscular weakness’ (shortened to ‘Weakness’), ‘Concentration’, ‘Effects of heat’
and ‘Rest’. Of the original five factors, two factors ‘Energy’ and ‘Weakness’ met the expectations of the Rasch model.
A higher order fatigue summary scale, consisting of items from the ‘Energy’ and ‘Weakness’ subscales, was found
to fit the Rasch model and have acceptable unidimensionality. The two scales and the higher order summary scale
were shown to fulfil model expectations, including assumptions of unidimensionality, local independency and an
absence of differential item functioning.
Conclusions: The Neurological Fatigue Index for MND (NFI-MND) is a simple, easy-to-administer fatigue scale. It
consists of an 8-item fatigue summary scale in addition to separate scales for measuring fatigue experienced as
reversible muscular weakness and fatigue expressed as feelings of low energy and whole body tiredness. The
underlying two factor structure supports the patient concept of fatigue derived from qualitative interviews in this
population. All three scales were shown to be reliable and capable of interval level measurement.
Introduction
Fatigue is one of the most commonly reported symp-
toms in motor neurone disease (MND) [1,2]. The etiol-
ogy of this symptom is not yet fully understood and its
progression and symptom salience varies between indivi-
duals. It has been shown to be associated with poor
quality of life (QoL) [1], though there is some debate as
to its precise relationship with concomitant disease fac-
tors, including depression [2].
Fatigue is an essentially subjective phenomenon; clini-
cally, it remains undefined due to the overlap between
the lay notion of tiredness and the clinically relevant
symptom of fatigue [3]. In addition, fatigue may con-
found with loss of motivation or other symptoms. The
symptom of fatigue extends beyond just muscular
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any medium, provided the original work is properly cited.fatigability or weakness, it is distinct from depression
and does not necessarily correlate with severity of dis-
ease [4]. Recent evidence supports the notion that fati-
gue in MND is an independent factor not directly
associated with depression, dyspnoea or sleepiness [2].
The lack of research relating to fatigue in this popula-
tion may be due in part to lack of tools available to
accurately measure the experience of fatigue in MND.
There are currently no MND-specific scales for measur-
ing fatigue and it is long established that generic ques-
t i o n n a i r e sm a yb ei n s e n s i t i v et ot h eu n i q u ee x p e r i e n c e
of a patient with MND [5]. Similarly it has been demon-
s t r a t e dt h a tt h ee x p e r i e n c eof fatigue may differ among
neurological conditions [3]. In light of these considera-
tions, there is a clear need to develop and validate a dis-
ease specific fatigue inventory for patients with MND.
Without access to a valid tool for measuring and com-
paring levels of fatigue in this population, there is little
hope for developing better treatment modalities that will
allow this disabling symptom to become better
managed.
The objective of this research is to develop a disease-
specific measure for fatigue in patients with motor neu-
rone disease (MND) by generating data that would fit
the Rasch measurement model
Methods
The Neurological Fatigue Scale for MND (NFI-MND)
was developed in two stages: a confirmatory qualitative
phase followed by a stage of formal psychometric assess-
ment. Ethical permission was granted for both phases
from relevant hospital committees in the U.K. (Sefton
05/Q0401/7 and Tayside 07/S1402/64), and local
research governance committees at all participating
sites.
Qualitative methodology was used to assess patient
perception of fatigue in MND. A sample of 10 patients
who had reported experiences of fatigue were inter-
viewed at the time of their clinical visit. Participants all
had a diagnosis of MND from a neurologist with exper-
tise in MND. The interviews commenced with an open-
ended question asking patients to describe their experi-
ence of fatigue. The interviews were then extended into
a semi-structured format in which issues relating to fati-
gue derived from interviews with other samples of
patients with neurological illness (including multiple
sclerosis (MS), and stroke) were explored with the
patients. In accordance with interpretative phenomeno-
logical analysis (IPA) guidelines [6] an ap r i o r isample
of ten patients was hypothesised to be sufficient to
investigate the phenomenon of fatigue in patients with
MND.
All patients who completed the qualitative interviews
were then presented with the original pool of 52 items
related to fatigue, developed initially for use in MS [7].
They were asked to comment on the relevance of the
i t e ms e tf o rM N Da n dw h e t h e ro rn o tt h ei t e m sw e r e
understandable. The qualitative methodology is
described in further detail elsewhere [8]. In addition, the
M N Dq u a l i t a t i v ed a t aw e r ec o m p a r e dt op r e v i o u s l y
derived themes in MS for the emergence of new themes.
The psychometric and scaling properties of the pro-
posed 52-item NFI-MND were then assessed among
patients recruited from five regional MND care centres:
T h eW a l t o nC e n t r ef o rN e u r o l o g ya n dN e u r o s u r g e r yi n
Liverpool, Preston Royal Hospital, Oxford John Radcliffe
Hospital, Salford Hope Hospital and Sheffield Royal Hal-
lamshire Hospital. Patients were eligible to enter the
s t u d yi r r e s p e c t i v eo fa g e ,s e x ,a n dd i s e a s es u b - t y p eo r
disability status. Questionnaires were either handed out
during a routine clinic appointment or sent to the
patient’s home, as part of a larger questionnaire pack
sent alongside a newsletter describing the research activ-
ities of their local care centre. A subsample of patients
completed The Modified Fatigue Impact Scale [9]. Two
to four weeks after completing the first questionnaire
patients were invited to complete a second question-
naire to assess test-retest reliability.
The Rasch measurement model was used to evaluate the
scaling properties and construct validity of the 52-item
draft questionnaire [10]. The Rasch model supplements
the traditional psychometric assessments of reliability and
construct validity by also evaluating the fundamental scal-
ing properties of an instrument. The model operationalises
the formal axioms of measurement (order, unidimension-
ality and additivety) allowing interval level data to be
gained from questionnaires [11]. In the context of fatigue,
the Rasch model simply states that the probability of a
person affirming an item is a logistic function of the symp-
tom severity the person experiences and the severity of the
symptom measured by the question. For example if a per-
son with a very low level of fatigue attempts a question
that expresses a high level of fatigue, there is a high prob-
ability that they will not affirm the item. A detailed expla-
nation and a more comprehensive review of Rasch
methods may be found elsewhere [12].
To assess external validity, a visual analogue scale
(VAS) of fatigue was included with the questionnaire
pack. The question was marked on a 0-100 scale and
prompted respondents to “Mark on the line, how severe
you fatigue has been over the past 4 weeks”.T h eV A S
extremes were marked as ‘Lively and alert’ at the lower
extreme and ‘Absolutely no energy to do anything at all’
at the upper.
Analysis Procedure
An initial exploratory factor analysis (EFA) based on a
polychoric correlation matrix was undertaken followed
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stage is to avoid bringing to the Rasch analysis any ser-
ious multidimensionality. Thus an EFA is undertaken to
give an indication of the dimensionality of the draft
scale prior to more rigorous tests of unidimensionality
within Rasch analysis [13]. Consequently a parsimonious
solution is sought from the EFA, where a root mean
square error of approximation (RMSEA) value below .10
is considered suitable [14].
Fit to the Rasch model
Data are required to meet Rasch model expectations,
and a number of fit statistics are used for this purpose.
Fit is indicated by a non-significant summary chi-square
statistic. Person and Item fit is also represented by resi-
dual mean values, where the summary fit standard
deviation falls below 1.4, and individual person and item
residuals fall within the range of ± 2.5.
Local dependency
An assumption of the Rasch model is that items are
locally independent, conditional upon the trait being
measured (i.e. f a t i g u e ) .T h i si si d e n t i f i e db yr e s i d u a l
item correlations of +.3 and above. Where local depen-
dency occurs items are too similar, and this artificially
inflates reliability. This can be accommodated by sum-
ming the items together into one ‘super’ item, known as
a testlet.
Differential Item Functioning (DIF) [15]
Differential Item Functioning (DIF) occurs when differ-
ent groups within the sample (e.g. males and females)
respond in a different way to a certain question, given
the same level of the underlying trait (i.e. fatigue). DIF
occurs where there is difference in responses across
groups. DIF would occur, for example, if men consis-
tently give a higher score to an item than women,
regardless of their level of fatigue. Analysis of variance
(ANOVA, 5% alpha) is used to measure DIF. In the cur-
rent study DIF was assessed for five factors: Test/Retest;
Location (Liverpool, Oxford/Preston/Salford/Sheffield);
Mode of Administration (clinic/delivered to home); Age
(quartile split between participants) and Gender. Differ-
ential item functioning is used to examine contextual
factors for invariance, preventing such factors being a
source of confounding effect in the phenomenon being
measured.
Item Category Thresholds
The Rasch model also allows for a detailed analysis of
the way in which response categories are understood by
respondents. For example, in the case of a Likert style
response, some respondents may have difficulty differen-
tiating between categories, such as “Never” or “Very
Rarely”. In instances where there is too little discrimina-
tion between two response categories on an item, col-
lapsing the categories into one response option can
often improve scale fit to the Rasch model.
Person Separation Index
This indicates the extent to which items distinguish
between distinct levels of functioning (where .7 is con-
sidered a minimal value for group use; .85 for individual
patient use).
Unidimensionality
Finally, a series of independent t-tests are employed to
assess the final scale for unidimensionality. Two esti-
mates are derived from items forming high positive and
high negative loadings on the first principal component
of the residuals. These are compared and individual t-
tests calculated. The number of significant t-tests out-
side the ± 1.96 range indicates whether the scale is uni-
dimensional or not. Generally, less than 5% of
significant t-tests are considered to be unidimensional
(or the lower bound of the binomial confidence interval
overlaps 5%) [12].
Scale item reduction
Items are removed where necessary one at a time. Once
an item is removed from a scale the resultant scale is
reassessed for fit, dimensionality, local dependency and
DIF. This iterative process is repeated until an accepta-
ble solution is found for the scale.
The unrestricted ‘partial credit’ Rasch polytomous
model was used with conditional pair-wise parameter
estimation [16]. Rasch Unidimensional Measurement
Model 2020 (RUMM2020) software (Version 4.1, Build
194) was used for the Rasch analyses presented in this
study [17].
Results
Qualitative item validation
All themes in the item set were confirmed as being rele-
vant to MND patients. All ten patients agreed that the
areas covered by the 52 items were sufficient to capture
all of their own personal experiences of fatigue, and no
additional themes emerged from the interviews. A sum-
mary of the item framework, features, wording and sup-
porting quotes taken from the qualitative investigation
are given in Table 1. All patients filled out the draft
scale and commented that all items were easy to under-
stand and were relevant to their experience.
Quantitative scale validation
Patients
For the main data collection, 278 questionnaires sent to
the patient’s homes were returned, and a further 20 were
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544 questionnaires were sent to patients (54.7% response).
Completeness for the 52 items of the MND NFI was
98.53%. To assess test-retest validity, 78 patients com-
pleted the pack for a second time after a period of 4-6
weeks. One hundred and eighty five participants com-
pleted the MFIS. The average age of participants was 62.1
± 11 years. In total, 186 respondents (62.1%) were male.
Contemporaneous functional status information for 141
patients (25 at retest) was collected from clinical notes no
more than 1 month prior to or following completion of
the questionnaire (Amyotrophic Lateral Sclerosis Func-
tional Rating Scale Revised - ALSFRS-R [15]). Summary
demographic information and questionnaire response by
centre is displayed in Table 2.
Exploratory factor analysis
The data from the 298 respondents were subjected to an
exploratory factor analysis (EFA). This indicated an
acceptable 5-factor solution with an RMSEA of .10. The
factors were thematically conceptualised to reflect ‘Lack
of energy’ (15 items), ‘Weakness’ (9 items), ‘Effects of
Heat’ (4 items), ‘Concentration’ (4 items) and ‘Rest’ (4
items).
Rasch Analysis
Rest and Concentration Subscales Only 4 items loaded
exclusively onto each of the ‘Rest’ and ‘Concentration’
subscales. Due to the small number of items loading on
each factor, after dealing with misfitting items, neither
subscale could be reconciled to meet Rasch model
demands.
Effects of Heat Subscale The ‘Effects of Heat’ compo-
nent was omitted from the Rasch analysis of the final
scale based on qualitative evidence that for patients with
MND, that extreme temperature was an effect modifier
(i.e. made fatigue better or worse) rather than directly
related to fatigue. In addition only 4 items loaded to
this subscale.
Data for the ‘Energy’ and ‘Weakness’ domains were
then fitted to the Rasch measurement model. An itera-
tive process of item reduction involved identifying disor-
dered thresholds, differential item functioning, item
misfit, breaches of local dependency and multidimen-
sionality. A summary of findings related to the analysis
of both domains, and the final summary scale, are given
in Table 3.
Table 1 Comparison of Item framework, feature, wording and supporting quotes
Framework Feature Example item Supporting quote
Motor features Can develop
weakness
Sometimes, I lose my body
strength
I have lost the ability to sustain [my strength]
Cognitive
features
Concentrate on
simple tasks
Sometimes, I have to concentrate
on what are usually simple things
When reading a magazine or something and I’m getting tired then I find
it more difficult to concentrate, it’s just more difficult when I’m tired.
Motivation Thought puts off
doing
The thought of having to do
something often puts me off
doing it
[Because of] what’s happened to get the fatigue you are less likely to want
to do the same things anyway.
Tiredness Tiredness By the end of the day, I’m
shattered
Just tiredness, all the time tiredness
Cadence Carry over If I’ve overdone things, I know
about it the next day
I try not to do too much, because that’d knacker me up for the next day
then
Precipitating/
aggravating
factors
Physical exertion
induces
weakness
I soon become weak after
physical effort
[I get fatigued] when doing anything physical, it’s surprising that the
things I never used to regard as physical are now physical and causing
fatigue.
Relieving factors day rest
restorative
Resting allows me to carry on [I’d rest for] maybe three to four minutes, something like that. I make sure
that it is long enough if it’s any shorter then I’m back to square one; it
feels like I am not recharged enough.
Severity weak at rest I can become weak even if I’ve
not been doing anything
Now you just do very minimal things that you wouldn’t consider as
anything and you feel fatigued
Associated
features
Unrefreshing
nocturnal sleep
When I wake in the morning, I
get the weariness feeling
I wake up in the morning, and get this weariness feeling
Table 2 Demographics and questionnaire response per
centre.
Demographics Test Retest
Age (years) 62.1 ± 11 63.2 ± 10.5
Sex 62.4% male 64.9% male
Returned 298 82
Clinic 20 0
Home 278 82
ALSFRS-R 32.72 ± 8.27* 31.92 ± 9.89**
Disease duration (years) 2.69 ± 3.54 2.73 ± 2.88
Centre Liverpool 110 36
Sheffield 38 5
Oxford 39 9
Manchester 76 13
Preston 35 15
* N = 141 ** N = 25
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model was poor, with person and item means exceeding
the expected values. The item set displayed multidimen-
sionality (see Table 3. Analysis 1). An iterative process
led to scale reduction of 9 items. The resulting ‘Energy’
subscale showed good fit to model expectations, includ-
ing unidimensionality, ordered category thresholds as
well as an absence of both differential item functioning
(DIF) and local dependency (see Table 3. Analysis 2).
Principal component analysis revealed that 63.37% of
the variance in fatigue was explained by the energy sub-
scale. Individual item fit statistics for the Energy sub-
scale are presented in Additional File 1.
Weakness Subscale All thresholds were correctly
ordered for the nine item scale. Two items: ’I have pro-
blems with my speech when I am tired’ and ’The cold
m a k e sm yb o d yv e r ys t i f f ’ displayed substantial misfit to
the Rasch model and failed to meet scale expectations
(Table 3, Analysis 3). Removal of the misfitting items
improved fit of the scale, yielding strict unidimensional-
ity, no DIF, and supported the local independence
assumption (Table 3, Analysis 4). The weakness subscale
accounted for 52.79% of the variance of fatigue. Indivi-
dual item fit statistics for the Weakness subscale are
presented in Additional File 1.
Summary Scale All items from the ‘Weakness’ and
‘Energy’ subscales were then included as potential items
for a summary fatigue scale (a higher-order factor). The
13 items showed reasonable fit to the Rasch model,
though the standard deviation of the item fit residual
was above the expected value. An iterative procedure
reduced the summary scale to 8 items, producing a uni-
dimensional scale with excellent fit to the Rasch model
(Table 3, Analysis 6). Principal component analysis
revealed that 52.09% of the variance in fatigue was
explained by the summary scale. Individual item fit sta-
tistics for the summary scale are presented in Additional
File 1.
Scale Targeting The three final scales (Weakness,
Energy and the Summary scale) showed acceptable per-
son-item targeting (see Figure 1. for example) with
extreme scores less than 5% in all cases. In Figure 1 per-
son locations are shown above the x-axis and represent
the amount of fatigue patients have, bars below the x-
axis represent item threshold location (the amount of
fatigue measured by the items). Good scale targeting is
indicated by a good spread of item threshold locations
that correspond to person locations above the x-axis.
Person-item threshold distribution graphs for the Weak-
ness and Summary scales are provided in Additional
Files 2 and 3.
Test-Retest reliability Retesting was performed between
two and four weeks. The invariance of the scales over
time was confirmed by the absence of DIF by time.
Test-retest reliability was good, with correlation coeffi-
cients all above .65. There were no significant differ-
ences in the mean scores (median for Energy subscale)
between time points (Paired Samples T-Test and Wil-
coxon Signed Rank; p > 0.05 (see Table 4).
Bland and Altman [18] analysis was conducted to
assess test-retest repeatability. Mean differences did not
exceed 1 point on the 100 point scale, meaning they
were clinically insignificant (see Table 4). For all three
scales 89-95% of cases fell within the 95% confidence
interval constructed for a normal distribution. Bland
Altman plots for the three scales are available in Addi-
tional Files 4, 5 and 6.
Table 3 Summary Analysis figures for Rasch analyses of the NFI:MND
Item Residual Person Residual Chi Square PSI Unidimensional t-test (CI%) % extreme scores
Analysis Name # of items Mean ± SD Mean ± SD Value p
1. Energy Initial 15 -0.34 2.21 -0.46 1.61 91.94 < 0.0001 0.93 9.34% (7-12) 0.80%
2. Energy Final 6 0.25 1.08 0.46 1.13 12.63 0.81 0.88 3.86% 4.40%
3. Weakness Initial 9 0.41 2.74 0.27 1.30 106.5 < 0.0001 0.86 2.79% 3.70%
4. Weakness Final 7 -0.08 1.36 -0.41 1.15 29.24 0.11 0.86 4.24% 5.10%
5. Summary Initial 13 -0.72 1.56 -0.42 1.38 70.22 0.04 0.92 4.44% 1.70%
6. Summary Final 8 0.11 1.25 -0.4 1.20 32.93 0.42 0.86 5.15% (3-8) 2.40%
Ideal Values 0 < 1.4 0 < 1.4 > 0.05
a > 0.85 < 5% (CI < 0.05)
a = Bonferroni corrected
Figure 1 Person-item threshold distribution for Energy
subscale.
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any of the five examined person factors for any of the
scales, indicating the NFI-MND may be administered to
patients in the U.K. regardless of age or gender, at a
clinic appointment or at the patient’sh o m ev i ap o s t a l
administration.
External construct validity To assess external construct
validity, raw scores on the NFI-MND were compared to
those from a VAS measure of fatigue using Pearson’s
product-moment correlation. The summary, energy and
weakness subscales correlated with VAS scores for fati-
gue to a magnitude of .60, .65 and .54 respectively. One
hundred and eighty five respondents also completed the
Modified Fatigue Impact Scale (MFIS) [9] at the same
time as the MND-NFI. Pearson product moment corre-
lations between the scales of the MNDNFI and the
MFIS were strong (Energy r = .66, p < 0.0001; Weakness
r = .71, p < 0.0001; Summary r = .75, p < 0.0001).
The relationship between the NFI-MND scales and
the ALSFRS-R measure of functional status was
explored using data collected from hospital notes for
141 of the study participants. Pearson’sc o r r e l a t i o n
values using raw score data reveal that functional status
correlated mildly with the summary fatigue scale (r =
-.18, p = 0.03) and the weakness subscale (r = -.23, p =
0.005), the energy subscale did not correlate significantly
with functional ability (r = -.07, p = 0.41). In accordance
with past research, these results suggest that there is no
simple linear relationship between fatigue and functional
status for patients with MND [2].
Raw score to interval scale conversion Table 5 pro-
vides a simple chart for allowing conversion of raw
scores taken from each of the three scales into interval
level scores for use in arithmetic operations. These con-
versions will hold provided there is no missing data. Use
in parametric analyses will also require appropriate dis-
tributional properties.
Discussion
The purpose of this study was to develop and validate a
disease-specific instrument for measuring fatigue in
patients with MND. Qualitative analysis confirmed the
suitability of a previously identified 52-item neurological
fatigue set. Rasch model expectations were met after
correctly ordering the item set into salient factors and
removing misfitting items.
As expected for this functionally limited population,
the themes of the final scale were not heavily focussed
around fatigue following strenuous exercise. Generic
instruments, such as the Fatigue Severity Scale [19],
include items assessing fatigue following levels of exer-
tion that are simply not possible for patients in the
later, disabling stages of MND. For example, the Multi-
dimensional Fatigue Inventory [20] measures fatigue
over 20 items split into 5 dimensions; General Fatigue,
Table 4 Test-retest comparison for NFI:MND
Scale T1-T2 Correlations Mean Scores T1, T2 SD (q1-q3) Mean difference % of cases falling within 95% confidence interval
Summary 0.84* 14,14
a 9.79 (7-13) 0.10 94.03%
Energy 0.67** 10,10
b 13.09 (11-16) 0.15 89.66%
Weakness 0.86* 13,13
a 17.42 (14-21) 0.10 92.54%
* Pearson’sr
**Spearman’s Rho
a Paired Samples T-Test; p > 0.0001
b Wilcoxon Signed Rank; p > 0.0001. Note median score used due to sample distribution
Key - SD = Standard deviation, q1 = Quartile One, q3 = Quartile Three
Table 5 Conversion table for raw to interval scores.
Raw Score Summary Scale Weakness Subscale Energy Subscale
0 0.00 0.00 0.00
1 2.05 1.88 1.53
2 3.56 3.29 2.79
3 4.66 4.35 3.83
4 5.59 5.24 4.80
5 6.41 6.04 5.75
6 7.17 6.78 6.70
7 7.90 7.50 7.61
8 8.62 8.20 8.48
9 9.34 8.91 9.31
10 10.07 9.63 10.14
11 10.81 10.36 10.97
12 11.58 11.13 11.81
13 12.36 11.91 12.63
14 13.16 12.73 13.45
15 13.98 13.58 14.29
16 14.80 14.47 15.24
17 15.62 15.41 16.45
18 16.44 16.43 18.00
19 17.28 17.59
20 18.17 19.08
21 19.16 21.00
22 20.32
23 21.89
24 24.00
Table 5 may be used to translate raw total scores taken from the
questionnaires into interval level scores suitable for use in mathematic
operations. NB: Only valid with complete data.
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and Reduced Activity. Our qualitative findings suggest
that patients with MND not only make minimal refer-
ence to activity determined fatigue in the classical sense
(i.e. following exercises such as running) but report
fewer experiences of mental fatigue than patients with
other neurological disorders, such as multiple sclerosis
[21].
There are some of limitations to the study. Whilst we
endeavoured to obtain a representative sample, most
patients were recruited initially either at a routine clinic
appointment or where the patient was known to the
clinical team to be interested in research. Selecting
patients in this manner may have caused the sample to
be skewed toward patients who were at early stages of
the disease rather than those nearing the end stage of
the disease, although ALSFRS-R scores suggested a wide
spread of disability within our sample. Additionally, the
number of ALSFRS-R responses restricts the power of
correlations to detect changes below magnitudes of r =
0.2. However, other researchers [2] have found there to
be no significant relationship between functional status
and fatigue in patients with MND.
Scores for test-retest reliability for the Energy subscale
were slightly below expected values. Test-retest reliabil-
ity analyses were carried out between two to four weeks
after the completion of the original questionnaire. The
rapidly progressive nature of MND could mean that, for
some patients, a large increase in this aspect of fatigue
may occur within a four week period. The current study
may have been improved by collecting test-retest data
over a shorter time period, in order to minimise the
effects of the rapid natural progression of the disease
upon the results of test-retest reliability analyses.
Differential item functioning analyses in this study
were limited by the small sample sizes in the clinic com-
pletion group, which contained only twenty patients.
Small numbers are apparent in this group due to the
difficulties of administering a suite of questionnaires,
including a 52-item fatigue measure, in a short clinic
appointment. Many patients expressed a preference to
take the pack home to complete. The thirteen items of
the MND-NFI are now more suitable for clinic adminis-
tration and further work may usefully examine the valid-
ity of the MND-NFI for clinician administration, as well
as patient self-complete.
An important caveat of disease specific outcome mea-
sures is their inability to provide comparisons between
disorders [22] that may serve to foster a more complete
understanding of fatigue and its mechanisms. However,
the Rasch model is capable of addressing this problem
and allowing for comparisons to be made across differ-
ent disease groups, especially if the scales have been
derived in such a manner as to share common items
[23]. Further progress could be made using the initial 52
questionnaire items to form the basis of other Rasch
validated disease-specific scales for neurological condi-
tions such as stroke and post-polio syndrome; allowing
for both disease-specific measurement and inter-disease
comparison. To this end, the Neurological Fatigue Index
for Multiple Sclerosis (NFI-MS) was derived from the
same initial 52 item bank and separately validated speci-
fically for use in multiple sclerosis [7]. The NFI-MS
measures fatigue over four domains revealed to be sali-
ent to patients with MS; ‘Physical’, ‘Cognitive’, ‘Relief by
diurnal sleep or rest’ and ‘Abnormal nocturnal sleep and
sleepiness’, although the latter two scales were acknowl-
e d g e dt ob eo n l yp r o v i s i o n a l ,a n dm a yi n d i c a t ea d a p t i v e
processes, rather than aspects of fatigue itself. Further
work is warranted to compare fatigue as experienced by
patients with MND, MS and other neurological illnesses.
In the NFI-MND the simple duality of the ‘Weakness’
and ‘Energy’ subscales will also assist clinicians in asses-
sing what patients mean when they describe feelings of
fatigue. As such the NFI-MND fatigue scale may serve
as a valuable tool for assessing the patient experience of
fatigue and how this disabling symptom changes over
time in clinical settings, clinical trials and in bio-psycho-
social research studies. This is facilitated further by the
transformation of the ordinal raw scores into interval
level measurement.
Importantly, the MND-NFI is a brief measure, con-
taining only 13 items, with only 8 items in the summary
scale. Questionnaire length is an important concern for
patients with MND, particularly when they are suffering
from fatigue [22]. The brevity of the MND-NFI makes it
appropriate for routine clinical application in this popu-
lation, but the scale may also be used in clinical trials,
whilst the full NFI-MND may lend itself to bio-psycho-
social and biological studies.
Given that all three scales fit the Rasch model, the raw
score from each scale is sufficient for identifying the
ordinal level of fatigue, energy or weakness a patient
exhibits. This ordinal score is convenient for ‘everyday’
use and will give a good indicator of the levels of fatigue
displayed by the respondents. Whenever parametric sta-
tistics are required for the data, the ordinal-interval con-
version can be employed, in the event there are no
missing data.
Conclusion
The NFI-MND is a brief, easy-to-administer fatigue
scale for patients with MND. It consists of an 8-item
fatigue summary scale in addition to separate scales for
measuring fatigue as experienced as reversible muscular
weakness and fatigue expressed as feelings of low energy
and whole body tiredness. The underlying two factor
structure supports the patient concept of fatigue derived
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scales were shown to be reliable and capable of interval
level measurement and are suitable for use in clinics or
research.
Implications for practice and research
The summary scale for the MND-NFI is suitable for use
in both a clinical and research settings. Given fit to the
Rasch model, the raw score is sufficient for identifying
the ordinal level of fatigue in patients by simply adding
the scores from the questionnaire. Where parametric
statistics are required, a nomogram is provided for ordi-
nal-interval transformation. The NFI-MND is free for
use in all public health and not-for-profit agencies, and
can be obtained from the authors following a simple
registration.
Additional material
Additional file 1: Item Fit Statistics for NFI-MND. Individual item fit
statistics for the Energy, Weakness, and Summary scales.
Additional file 2: Person-Item Distribution for Weakness subscale.
Illustration of Person-Item threshold distribution for the Weakness
subscale.
Additional file 3: Person-Item Distribution for Summary scale.
Illustration of Person-Item threshold distribution for the Summary scale.
Additional file 4: Bland-Altman plot for Energy subscale. Bland-
Altman plot showing agreement between test and retest scores for the
Energy subscale.
Additional file 5: Bland-Altman plot for Weakness subscale. Bland-
Altman plot showing agreement between test and retest scores for the
Weakness subscale.
Additional file 6: Bland-Altman plot for Summary scale. Bland-Altman
plot showing agreement between test and retest scores for the
Summary scale.
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